TrialNature medicine2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
Lotte L Hoeijmakers et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it